Results 231 to 240 of about 41,565 (267)

The efficacy of azathioprine in relapsing ‐ remitting multiple sclerosis

Neurology, 1991
We randomized 59 patients with relapsing-remitting multiple sclerosis to receive azathioprine (AZA) 3.0 mg/kg daily or placebo in a double-masked therapeutic trial. Analysis of data for predetermined primary outcome measures demonstrated a significant difference favoring AZA for observed mean exacerbation rate after 2 years of therapy and time to ...
D E, Goodkin, R C, Bailly, M L, Teetzen, D, Hertsgaard, W W, Beatty   +4 more
openaire   +2 more sources

Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis

Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2016
This review includes results of experimental and clinical studies of dimethyl fumarate, a new oral drug for pathogenetic treatment of multiple sclerosis (MS). The mechanism of action, data from clinical trials, including MRI-results related to tolerability and safety of the drug are reviewed.
E V, Popova, A N, Boyko, E V, Orlova
openaire   +2 more sources

Immunomonitoring measures in relapsing-remitting multiple sclerosis

Journal of Neuroimmunology, 2004
Forty-five patients with relapsing-remitting multiple sclerosis (MS) were examined to determine intracellular cytokine profiles and the surface phenotype of circulating lymphocytes during active, recovery, and stable stages. Active stage patients were characterized by decreases in CD4(+)IL-4(+) Th2 as well as CD4(+)IFN-gamma(+) Th1 cells, when compared
Makoto, Matsui, Shin-ich, Araya, Hui-Yun, Wang, Kouji, Matsushima, Takahiko, Saida   +4 more
openaire   +2 more sources

Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis

Drugs, 2020
Alemtuzumab (Lemtrada®) is an anti-CD52 monoclonal antibody approved in the EU for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS). In phase 3 trials in patients with active RRMS, intravenous alemtuzumab was more effective than subcutaneous interferon β-1a in terms of decreasing relapse rates (in treatment-naïve or ...
openaire   +2 more sources

TRAF2 is Upregulated in Relapsing-Remitting Multiple Sclerosis

Neuroimmunomodulation, 2013
<b><i>Objective:</i></b> To elucidate the role of tumor necrosis factor (TNF) receptor signal transduction in multiple sclerosis (MS). <b><i>Methods:</i></b> We performed a cross-sectional analysis of the gene expression of TRAF2 (TNF receptor-associated factor 2) and RIP (receptor-interacting protein) in
Reinhard, Reuß, Andreas, Mirau, Marta, Mistarz, Jörg, Kraus, Rolf-Hasso, Bödeker, Patrick, Oschmann   +5 more
openaire   +2 more sources

Alemtuzumab in the treatment of relapsing–remitting multiple sclerosis

Expert Review of Neurotherapeutics, 2010
Multiple sclerosis (MS) is an autoimmune disorder characterized by CNS inflammation, demyelination and cellular damage with atrophy. Most patients with MS initially present with a relapsing-remitting course, with periodic episodes of neurologic symptomatology that do not follow a predictable pattern. In order to maintain a stable clinical course, it is
openaire   +2 more sources

Mycophenolate mofetil for relapsing-remitting multiple sclerosis

Cochrane Database of Systematic Reviews, 2012
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system and a leading cause of disability in young and middle-aged adults. Mycophenolate mofetil (MMF) is an immunosuppressive agent that has been used for the prevention of allograft rejection after renal, cardiac, or liver transplant and in patients with autoimmune diseases ...
Yousheng, Xiao, Jianyi, Huang, Hongye, Luo, Jin, Wang   +3 more
openaire   +2 more sources

Considerations in the treatment of relapsing-remitting multiple sclerosis

Neurology, 2002
Disease-modifying drugs are available in the United States for the treatment of relapsing-remitting multiple sclerosis (RRMS), including interferon (IFN) beta-1a, IFNbeta-1b, and glatiramer acetate. Another formulation of IFNbeta-1a is available in Europe, Canada, and other countries.
openaire   +2 more sources

Daclizumab for the treatment of relapsing-remitting multiple sclerosis

Expert Opinion on Biological Therapy, 2017
Multiple sclerosis (MS) is a common inflammatory disease of the central nervous system. Over the last two decades, the number of therapeutic options for the treatment of relapsing remitting MS (RRMS) has been constantly growing, providing new treatment options to patients.
Marina, Herwerth, Bernhard, Hemmer
openaire   +2 more sources

Ozanimod for the treatment of relapsing remitting multiple sclerosis

Expert Opinion on Pharmacotherapy, 2018
Ozanimod is a selective sphingosine 1-phosphate receptor 1 and 5 modulator under development by Celgene, for the treatment of relapsing remitting multiple sclerosis. Extensive clinical experience has become available for the related compound fingolimod, favoring the sphingosine 1-phosphate therapeutic concept. Off-target effects have been attributed to
Ludwig, Rasche, Friedemann, Paul
openaire   +2 more sources